Apogee Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Apogee Therapeutics

11/08/2025 19:32

Apogee Therapeutics Inc APGE.OQ reported a quarterly adjusted loss of $1.13​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -60 cents.  The mean expectation of nine analysts for the quarter was for a loss of $1.08 per share. Wall Street expected results to range from $-1.48 to -95 cents per share.

Reported revenue was zero​; analysts expected zero.

Apogee Therapeutics Inc's reported EPS for the quarter was a loss of $1.13​.

The company reported a quarterly loss of $66.1 million.

Apogee Therapeutics Inc shares had fallen by 18.5% this quarter and lost 21.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 6.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Apogee Therapeutics Inc is $95.00, about 62.7% above its last closing price of $35.39

This summary was machine generated from LSEG data August 11 at 06:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.08
-1.13
Missed
Mar. 31 2025
-1.25
-0.95
Beat
Dec. 31 2024
-1.08
-1.19
Missed
Sep. 30 2024
-0.77
-0.86
Missed